NCT06549816View on ClinicalTrials.gov

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

November 28, 2025

Study Completion Date

November 28, 2025

Conditions
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckEsophageal Squamous Cell CarcinomaGastric AdenocarcinomaEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

sigvotatug vedotin

Sigvotatug vedotin is a antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to cells expressing integrin beta-6.

Trial Locations (3)

210029

Jiangsu Province Hospital, Nanjing

510120

Guangdong Provincial People's Hospital, Guangzhou

Unknown

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Seagen, a wholly owned subsidiary of Pfizer

INDUSTRY